Paj 1 soti nan 16 rezilta yo
BACKGROUND OF THE INVENTION
The invention is in the fields of neurology and pharmacology and relates to protecting the brain and central nervous system against damage due to ischemia and other neurological disorders in which energy-providing substrates (oxygen and glucose) are reduced or energy
FIELD OF THE INVENTION
The present invention relates to novel analogs of Glycyl-Prolyl-Glutamate (GPE) and methods of their use. Additionally, this invention relates to the use of these compounds and pharmaceutical compositions thereof in the treatment of diseases and conditions characterised by
INTRODUCTION
The present invention relates to methods of treating movement disorders which utilize famotidine or famotidine-related compounds. It is based, at least in part, on the discovery that famotidine ameliorates the symptoms and signs of Parkinson's Disease. In preferred embodiments of the
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the field of neuropsychiatry and relates specifically to methods for memory enhancement and treatment of memory deficits consequent to neurological disorders.
2. Description of the Background Art
The N-methyl-D-aspartate
This is a 371 application of PCT/EP95/01856, filed May 16, 1995. The present invention is concerned with tricyclic dicarbonyl derivatives of the general formulae ##STR2## wherein R.sup.1 and R.sup.2 each independently signify hydrogen, lower alkyl, lower alkoxy, nitro, trifluoromethyl, amino,
This is a National Phase Application filed under 35 U.S.C. .sctn.371 as a national stage of International Application No. PCT/KR2010/005889, filed Aug. 31, 2010, claiming the benefit from Korean Patent Application No. 10-2010-0047485, filed May 20, 2010, the entire content of each of which is hereby
This invention relates to novel (2-thienyl)alkylamine derivatives, processes for their preparation, pharmaceutical formulations containing them and their neuroprotective properties.
PRIOR ART
European Patent Application, publication number 0322582, discloses, among many other compounds,
FIELD OF THE INVENTION
The present invention provides compositions and methods for modulating the expression of HIF-1a. In particular, this invention relates to LNA oligonucleotides, which are specifically hybridisable with nucleic acids encoding HIF-1a. The LNA oligonucleotides have been shown to
FIELD OF THE INVENTION
The present invention provides compositions and methods for modulating the expression of HIF-1a. In particular, this invention relates to LNA oligonucleotides, which are specifically hybridisable with nucleic acids encoding HIF-1a. The LNA oligonucleotides have been shown to
FIELD OF THE INVENTION
The present invention provides compositions and methods for modulating the expression of HIF-1a. In particular, this invention relates to LNA oligonucleotides, which are specifically hybridisable with nucleic acids encoding HIF-1a. The LNA oligonucleotides have been shown to
This application is a divisional of U.S. patent application Ser. No. 11/271,686, filed on Nov. 9, 2005, which claims the benefit of U.S. Provisional Patent Application No. 60/626,563, filed Nov. 9, 2004; U.S. Provisional Patent Application No. 60/647,186, filed Jan. 25, 2005; U.S. Provisional Patent
FIELD OF THE INVENTION
The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The
CROSS-REFERENCES TO RELATED APPLICATIONS
This application is a U.S. National Stage application under 35 U.S.C. 371 of PCT/EP01/04293, filed Apr. 12, 2001 which claims priority to European Patent Applications 00203382.7, filed Sep. 29, 2000, and 00201325.8, filed Apr. 12, 2000.
FIELD OF THE
FIELD OF THE INVENTION
The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The
FIELD OF THE INVENTION
The present invention relates to novel peptidomimetics containing a macrocycle and methods of their use. This invention also relates to the neuroprotective activity of such compounds. More particularly, this invention relates to the use of these compounds and pharmaceutical